241 related articles for article (PubMed ID: 17505011)
1. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cooper JP; Reynolds CP; Cho H; Kang MH
Exp Biol Med (Maywood); 2017 Jun; 242(11):1178-1184. PubMed ID: 28429653
[TBL] [Abstract][Full Text] [Related]
3. Fenretinide-polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration.
Orienti I; Zuccari G; Bergamante V; Carosio R; Gotti R; Cilli M; Montaldo PG
Biomacromolecules; 2007 Oct; 8(10):3258-62. PubMed ID: 17883277
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
Formelli F; Cavadini E; Luksch R; Garaventa A; Villani MG; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2008 Sep; 62(4):655-65. PubMed ID: 18066548
[TBL] [Abstract][Full Text] [Related]
5. Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration.
Carosio R; Pistoia V; Orienti I; Formelli F; Cavadini E; Mangraviti S; Montaldo PG; Ognio E; Emionite L; Zuccari G
J Pharm Pharmacol; 2012 Feb; 64(2):228-36. PubMed ID: 22221098
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
Maurer BJ; Kang MH; Villablanca JG; Janeba J; Groshen S; Matthay KK; Sondel PM; Maris JM; Jackson HA; Goodarzian F; Shimada H; Czarnecki S; Hasenauer B; Reynolds CP; Marachelian A
Pediatr Blood Cancer; 2013 Nov; 60(11):1801-8. PubMed ID: 23813912
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.
Kummar S; Gutierrez ME; Maurer BJ; Reynolds CP; Kang M; Singh H; Crandon S; Murgo AJ; Doroshow JH
Anticancer Res; 2011 Mar; 31(3):961-6. PubMed ID: 21498721
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of anti-tumour effects of oral fenretinide (4-HPR) in rats with human neuroblastoma xenografts.
Ponthan F; Lindskog M; Karnehed N; Castro J; Kogner P
Oncol Rep; 2003; 10(5):1587-92. PubMed ID: 12883745
[TBL] [Abstract][Full Text] [Related]
9. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.
Di Paolo D; Pastorino F; Zuccari G; Caffa I; Loi M; Marimpietri D; Brignole C; Perri P; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M; Pagnan G
J Control Release; 2013 Sep; 170(3):445-51. PubMed ID: 23792118
[TBL] [Abstract][Full Text] [Related]
10. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
; Villablanca JG; Krailo MD; Ames MM; Reid JM; Reaman GH; Reynolds CP
J Clin Oncol; 2006 Jul; 24(21):3423-30. PubMed ID: 16849757
[TBL] [Abstract][Full Text] [Related]
12. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
13. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
[TBL] [Abstract][Full Text] [Related]
14. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
15. Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues.
Vratilova J; Frgala T; Maurer BJ; Patrick Reynolds C
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 808(2):125-30. PubMed ID: 15261805
[TBL] [Abstract][Full Text] [Related]
16. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide.
Rayburg M; Towbin A; Yin H; Maugans T; Maurer B; Nagarajan R; Weiss B
Pediatr Blood Cancer; 2009 Dec; 53(6):1111-3. PubMed ID: 19621427
[TBL] [Abstract][Full Text] [Related]
17. Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
Lewis KC; Hochadel JF
Cancer Res; 1999 Dec; 59(23):5947-55. PubMed ID: 10606240
[TBL] [Abstract][Full Text] [Related]
18. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
[TBL] [Abstract][Full Text] [Related]
19. Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles.
Okuda T; Kawakami S; Higuchi Y; Satoh T; Oka Y; Yokoyama M; Yamashita F; Hashida M
Int J Pharm; 2009 May; 373(1-2):100-6. PubMed ID: 19429294
[TBL] [Abstract][Full Text] [Related]
20. Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice.
Hultin TA; Filla MS; McCormick DL
Drug Metab Dispos; 1990; 18(2):175-9. PubMed ID: 1971569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]